ProShare Advisors
SPRO icon

ProShare Advisors’s Spero Therapeutics SPRO Stock Holding History

ProShare Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,608
Closed -$162K – 2239
2021
Q2 		$162K Buy
+11,608
New +$162K ﹤0.01% 2200

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ProShare Advisors's SPRO Position: Q3 2021 in Review

ProShare Advisors sold out of Spero Therapeutics (SPRO) in Q3 2021, closing a stake of 11,608 shares — an estimated $162K sold.

ProShare Advisors first reported a position in SPRO in Q2 2021 and held it in 1 quarter. The position peaked at $162K in Q2 2021. 87 funds tracked by Wall St. Rank hold SPRO as of Q3 2021.

  • ProShare Advisors reported no remaining Spero Therapeutics position as of Q3 2021 after selling out during the quarter.
  • ProShare Advisors sold 11,608 Spero Therapeutics shares in Q3 2021, an estimated $162K.
  • ProShare Advisors first reported a position in Spero Therapeutics in Q2 2021 and held it in 1 quarter.
  • ProShare Advisors's Spero Therapeutics position peaked at $162K in Q2 2021.
  • 87 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2021.

Based on ProShare Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.